Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real‐world case series
Francesca Palandri(Istituto Oncologico Romagnolo), Mario Tiribelli(University of Udine), Giulia Benevolo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Gabriele Fontana(ETH Zurich), Eloise Beggiato, Giuseppe A. Palumbo(University of Catania), Marian Loffredo(Istituto di Ematologia di Bologna), Erika Morsia(Marche Polytechnic University), Massimo Breccia(Policlinico Umberto I), Filippo Branzanti(University of Bologna), Alberto Dedola(Istituto di Ematologia di Bologna)
Cited by 6
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
|Journal of Clinical Oncology|2014|210
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|181
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
|American Journal of Hematology|2020|136